Lachesis Biosciences Is A Clinical Stage Biotechnology Company Targeting Dementia Caused By Alzheimer S And Parkinson S Disease Lachesis Biosciences Is Developing Lbio R32A Rivastigmine Nasal Spray For The Treatment Of Mild To Severe Alzheimer S Disease Dementia And Mild To Moderate Parkinson S Disease Dementialachesis Is Pursuing A 505 B2Development Pathway For Lbio R32Which Means The Company Can Substantially Rely On Existing Preclinical And Clinical Data Generated By Novartis With Rivastigmine For Approvalfrom A Development Standpointthis Takes Years And Hundreds Of Millions Off Their Plateit S A Significantly De Risked And Expedited Approach
No conferences found for this company.
| Company Name | Lachesis Biosciences Pty Ltd |
| Country |
Australia
|
| Address | N/A |
| Telephone | N/A |
| N/A |
